Shares of Zealand Pharma A/S (NASDAQ:ZEAL) have received an average broker rating score of 1.83 (Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. Zealand Pharma A/S’s rating score has declined by 22% in the last 90 days as a result of various analysts’ ratings changes.
Brokerages have set a 1-year consensus price objective of $27.33 for the company and are predicting that the company will post ($0.49) EPS for the current quarter, according to Zacks. Zacks has also given Zealand Pharma A/S an industry rank of 101 out of 265 based on the ratings given to its competitors.
A number of research firms recently weighed in on ZEAL. Needham & Company LLC began coverage on shares of Zealand Pharma A/S in a report on Tuesday, September 5th. They issued a “buy” rating and a $26.00 price objective on the stock. Guggenheim started coverage on shares of Zealand Pharma A/S in a research note on Tuesday, September 5th. They set a “buy” rating and a $28.00 target price on the stock. Zacks Investment Research upgraded shares of Zealand Pharma A/S from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a research report on Wednesday, November 15th. Goldman Sachs Group started coverage on shares of Zealand Pharma A/S in a research report on Wednesday, September 27th. They set a “buy” rating for the company. Finally, Morgan Stanley started coverage on shares of Zealand Pharma A/S in a research report on Tuesday, September 5th. They set an “overweight” rating and a $28.00 price objective for the company.
Institutional investors and hedge funds have recently made changes to their positions in the business. Susquehanna International Group LLP acquired a new position in shares of Zealand Pharma A/S in the third quarter worth about $3,185,000. Royce & Associates LP acquired a new position in shares of Zealand Pharma A/S in the third quarter worth about $1,152,000. Finally, Jane Street Group LLC acquired a new position in shares of Zealand Pharma A/S in the third quarter worth about $386,000. Institutional investors own 13.33% of the company’s stock.
Zealand Pharma A/S (ZEAL) traded down $0.10 during midday trading on Tuesday, reaching $14.01. 3,000 shares of the company’s stock were exchanged, compared to its average volume of 34,312. Zealand Pharma A/S has a 12-month low of $13.91 and a 12-month high of $20.37.
COPYRIGHT VIOLATION NOTICE: This report was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.thelincolnianonline.com/2017/12/07/zacks-brokerages-set-27-33-price-target-for-zealand-pharma-as-zeal-updated.html.
About Zealand Pharma A/S
Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.